Report #2837045

Received Apr 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 56 yrs
State: IL
Recovered: Unknown
Vaccinated: Feb 3, 2025
Onset: Feb 3, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

inappropriate vaccine schedule/2nd dose taken on 03 FEB 2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 56-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on 17 FEB 2023). On 03-FEB-2025, the patient received the 2nd dose of Shingrix. On 03-FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: inappropriate vaccine schedule/2nd dose taken on 03 FEB 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 14-APR-2025 The patient received first dose on 17 Feb 2023 and second dose on 03 Feb 2025. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.